A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL

Summary

This study is an open-label, multi-center, dose-ranging study to characterize the safety, tolerability, preliminary efficacy, and PK/PD of up to four dose levels of BNZ-1 administered weekly by IV infusion to adults diagnosed with Large Granular Lymphocyte (LGL) Leukemia or refractory Cutaneous T-cell Lymphoma (CTCL).

Timeline

Start

2018-04-01

Primary completion

2020-06-30

Completion

2020-06-30

Outcome

Met primary endpoint

release “completed Phase 1/2 study in cutaneous T cell lymphoma (CTCL), a dermato-oncology indication, achieving its primary objective of safety and tolerability” equilliumbio.com ↗

Publications

• Brammer JE, Ballen K, Sokol L, Querfeld C, Nakamura R, Mishra A, McLaughlin EM, Feith D, Azimi N, Waldmann TA, Tagaya Y, Loughran T. Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia. Blood. 2023 Oct 12;142(15):1271-1280. doi: 10.1182/blood.2022017643.

Drugs

Indications